Aims & Scope
Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary, peer-reviewed, biomedical journal
that reports new findings and cutting-edge concepts in all areas of
pharmacology. Special consideration is given to articles on pharmacogenomics
and personalized medicine. CPPM is an accelerator for global personalized
medicine and pharmacogenomics, as well as preclinical and clinical
pharmacology. Importantly, the journal provides a multi-disciplinary,
integrated platform from cell to society to address diagnostics and responsible
pharmacogenomics applications in developing countries and the entire range of
translational science from bench-to-bedside in various therapeutic areas such as
oncology, cardiovascular, neuropharmacology, endocrine diseases, amongst
others.
CPPM cooperates with the Ibero-American Network of
Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics
and welcomes peer reviewed contributions from authors in any global region.
The journal's scope is defined by four inter-connected
aims. First, we are interested in genomics/postgenomics biotechnologies and
diagnostics that enable global personalized medicine science (including and
beyond pharmacogenomics), as long as they explain person-to-person and
population differences in disease susceptibility or response to a health
intervention, and can be substantiated. Second, we approach personalized
medicine as ‘personalized health interventions’ focusing primarily on drug
therapy, but also other interventions such as nutrition, vaccines, surgical
devices, emerging cell-based therapies that collectively contribute to
healthcare. Third, we strive to integrate molecular and clinical investigation
with public policy, global health diplomacy and social studies of
biotechnology, that collectively shape postgenomics future(s) and innovation
trajectories in life sciences. Fourth, we are interested in all aspects of
translational pharmacology from preclinical to clinical applications in any
therapeutic area that will advance the practice of medicine for the benefit of
patients worldwide including non-communicable diseases as well as infectious
diseases in the post- COVID world.
Priority will be given to expert reviews/ mini-reviews and
research articles that include original ideas and findings related to the scope
and mandate of the journal. Unsolicited submissions are welcomed.
